TD Cowen Initiates Coverage On MapLight Therapeutics with Buy Rating

Benzinga Newsdesk www.benzinga.com Positive 56.7%

Neg 0% Neu 0% Pos 56.7%

TD Cowen analyst Joseph Thome initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating.

Comments

No comments yet. Be the first!